Skip to content
10-Q

Quarterly Report

Pharma-Bio Serv, Inc. PBSV

0001654954-26-002336

← back to feed
Filed
Mar 17, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Mar 13, 2026 22.9M sh
Shares Diluted Q1 2026 · Jan 31, 2026 22.91M sh
Shares Diluted Q1 2026 · Jan 31, 2025 22.96M sh
Stock Repurchased Q1 2026 · Jan 31, 2026 $1.68K
Stock Repurchased Q1 2026 · Jan 31, 2025 $0
Capex Q1 2026 · Jan 31, 2026 $2.41K
Capex Q1 2026 · Jan 31, 2025 $0
Operating Cash Flow Q1 2026 · Jan 31, 2026 −$390.14K
Operating Cash Flow Q1 2026 · Jan 31, 2025 −$429.49K
Stockholders Equity Q1 2026 · Jan 31, 2026 $10.24M
Stockholders Equity Q1 2026 · Oct 31, 2025 $11.91M
Stockholders Equity Q1 2026 · Jan 31, 2025 $12M
Stockholders Equity Q1 2026 · Oct 31, 2024 $13.72M
Current Liabilities Q1 2026 · Jan 31, 2026 $3.31M
Current Liabilities Q1 2026 · Oct 31, 2025 $1.74M
Total Liabilities Q1 2026 · Jan 31, 2026 $3.31M
Total Liabilities Q1 2026 · Oct 31, 2025 $1.74M
Current Assets Q1 2026 · Jan 31, 2026 $13.32M
Current Assets Q1 2026 · Oct 31, 2025 $13.39M
Total Assets Q1 2026 · Jan 31, 2026 $13.55M
Total Assets Q1 2026 · Oct 31, 2025 $13.65M
Eps Diluted Q1 2026 · Jan 31, 2026 $0.00
Eps Diluted Q1 2026 · Jan 31, 2025 $0.00
Sga Expense Q1 2026 · Jan 31, 2026 $816.91K
Sga Expense Q1 2026 · Jan 31, 2025 $860.3K
Net Income Q1 2026 · Jan 31, 2026 $32.86K
Net Income Q1 2026 · Jan 31, 2025 $8.54K
Operating Income Q1 2026 · Jan 31, 2026 −$94.54K
Operating Income Q1 2026 · Jan 31, 2025 −$92.19K
Gross Profit Q1 2026 · Jan 31, 2026 $722.37K
Gross Profit Q1 2026 · Jan 31, 2025 $768.11K
Cost Of Revenue Q1 2026 · Jan 31, 2026 $1.57M
Cost Of Revenue Q1 2026 · Jan 31, 2025 $1.7M
Revenue Q1 2026 · Jan 31, 2026 $2.29M
Revenue Q1 2026 · Jan 31, 2025 $2.47M
Dividends Paid restated Q1 2026 · Jan 28, 2025 $1.72M